Compare GLDD & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | MDXG |
|---|---|---|
| Founded | 1890 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2007 | 2007 |
| Metric | GLDD | MDXG |
|---|---|---|
| Price | $16.89 | $5.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $10.00 |
| AVG Volume (30 Days) | ★ 1.8M | 836.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 300.00 | N/A |
| EPS | ★ 0.90 | 0.22 |
| Revenue | ★ $702,503,000.00 | $348,879,000.00 |
| Revenue This Year | $13.16 | $19.13 |
| Revenue Next Year | $5.49 | N/A |
| P/E Ratio | ★ $18.77 | $23.50 |
| Revenue Growth | N/A | ★ 8.52 |
| 52 Week Low | $7.51 | $4.89 |
| 52 Week High | $16.99 | $8.46 |
| Indicator | GLDD | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 39.56 |
| Support Level | $16.85 | $5.10 |
| Resistance Level | $16.92 | $5.29 |
| Average True Range (ATR) | 0.37 | 0.18 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 95.82 | 77.11 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.